Larotrectinib in patients with TRK fusion-positive solid tumours

The Lancet Oncology in conversation with

English - April 07, 2020 10:00 - 13 minutes - 8.46 MB - ★★★★★ - 1 rating
Medicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The future of radiotheranostics

Next Episode: Peptide receptor radionuclide therapy for neuroendocrine tumours

Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a pooled analysis in The Lancet Oncology on the role of larotrectinib in patients with TRK fusion-positive solid tumours.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv